Switch theme
Sign up to access all valuation multiples
International Biotechnology Trust PLC is an investment trust company. It aims at achieving long-term capital growth by investing in biotechnology and other life sciences companies. It seeks to achieve its objective by investing in a diversified portfolio of companies which has good growth prospects. It focuses on investments in biotechnology companies which are engaged in on drug discovery and development, medical devices companies and healthcare services provider. The invests in various financial instruments such as equities, index-linked securities, debt securities, cash deposits, money market instruments ,and foreign currency exchange transactions. Its revenue comprises of dividend, interest and other income from investment made.
1994
n/a
Last FY Revenue $53.9M
Last FY EBITDA n/a
$314M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, International Biotechnology Trust achieved revenue of $53.9M and an EBITDA of n/a.
International Biotechnology Trust expects next 12-month revenue of XXX and NTM EBITDA of XXX
See International Biotechnology Trust valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $53.9M | XXX | XXX | XXX |
| Gross Profit | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | XXX | n/a | XXX | XXX | XXX |
| EBIT | XXX | n/a | XXX | XXX | XXX |
| EBIT Margin | XXX | n/a | XXX | XXX | XXX |
| Net Profit | XXX | $52.2M | XXX | XXX | XXX |
| Net Margin | XXX | 97% | XXX | XXX | XXX |
| Net Debt | XXX | $16.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, International Biotechnology Trust's stock price is GBP 6 (or $8).
International Biotechnology Trust has current market cap of GBP 198M (or $266M), and EV of GBP 234M (or $314M).
See International Biotechnology Trust trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $314M | $266M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, International Biotechnology Trust has market cap of $266M and EV of $314M.
International Biotechnology Trust's trades at 12.3x EV/Revenue multiple, and n/a EV/EBITDA.
Equity research analysts estimate International Biotechnology Trust's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
International Biotechnology Trust's P/E ratio is not available.
See valuation multiples for International Biotechnology Trust and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $266M | XXX | $266M | XXX | XXX | XXX |
| EV (current) | $314M | XXX | $314M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 12.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 11.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 7.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialInternational Biotechnology Trust's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
International Biotechnology Trust's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
International Biotechnology Trust's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for International Biotechnology Trust and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| XXX | XXX | XXX | XXX | XXX | XXX | |
| Waha Capital | XXX | XXX | XXX | XXX | XXX | XXX |
| CVC Capital Partners | XXX | XXX | XXX | XXX | XXX | XXX |
| EXOR | XXX | XXX | XXX | XXX | XXX | XXX |
| Pengana Private Equity | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
International Biotechnology Trust acquired XXX companies to date.
Last acquisition by International Biotechnology Trust was XXXXXXXX, XXXXX XXXXX XXXXXX . International Biotechnology Trust acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was International Biotechnology Trust founded? | International Biotechnology Trust was founded in 1994. |
| Where is International Biotechnology Trust headquartered? | International Biotechnology Trust is headquartered in United Kingdom of Great Britain and Northern Ireland. |
| Is International Biotechnology Trust publicy listed? | Yes, International Biotechnology Trust is a public company listed on LON. |
| What is the stock symbol of International Biotechnology Trust? | International Biotechnology Trust trades under IBT ticker. |
| Who are competitors of International Biotechnology Trust? | Similar companies to International Biotechnology Trust include e.g. , Waha Capital, CVC Capital Partners, EXOR. |
| What is the current market cap of International Biotechnology Trust? | International Biotechnology Trust's current market cap is $266M |
| Is International Biotechnology Trust profitable? | Yes, International Biotechnology Trust is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
